MedTrace Logo

Sitagliptin in Prevention of Type 2 Diabetes Mellitus

NCT01038648 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2015-12-30

No results posted yet for this study

Summary

The hypothesis is, in subjects with persistent impaired glucose tolerance(IGT) , sitagliptin will decrease the conversion rate to diabetes as compared to a placebo in three years.

Conditions

Interventions

DRUG

Sitagliptin

100mg/day

OTHER

life style modification at base line

Advice on physical activity, diet and drug adherence.

Sponsors & Collaborators

  • India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-02-28
Completion
2014-12-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01038648 on ClinicalTrials.gov